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A review of anaphylaxis in a clinic over three years was
performed. A co-factor for anaphylaxis stood out as a
commonality to all reactions. All five patients had a non
steroidal anti-inflammatory drug (NSAID) 24 hours
prior to immunotherapy.
Among symptoms, urticaria was the commonest; others
included cough, angioedema, dyspnea, nausea, vomiting,
hypotension and tachycardia. The symptoms appeared
within 5 minutes to two hours post-injection. All reactions
resolved after few hours. In all cases, NSAID use pre-injec-
tion was the only common factor. Two patients also had
moderate exercise post-injection, but previous immu-
notherapy was without incident. All but one patient were
administered epinephrine in clinic and recovered without
significant morbidity, some were also given cetirizine as
adjunct treatment and all were observed until symptoms
resolved. While two patients stopped immunotherapy,
three patients continued without incident and are now on
maintenance dose. The one patient who did not receive
epinephrine presented to a walk in clinic for her reaction
and received antihistamine treatment alone.
NSAID use, although overlooked in the literature, is a
common cofactor in anaphylaxis in response to immu-
notherapy. At Torontoallergists™, a clinic with three
allergists in practice, 5 such cases among approximately
3 600 injections in the last three years were noted after
extensive chart review. Therefore an NSAID was asso-
ciated with anaphylaxis in 0.0014% of the immunother-
apy injections, whereas two cases of anaphylaxis involved
NSAID and exercise involvement. No cases implicating
other risk factors or co-factors for anaphylaxis during
immunotherapy, such as dosage errors, or injection dur-
ing asthma exacerbation were present [1].
It is speculated that aspirin and other NSAIDS lower the
threshold for anaphylaxis after allergen injections through
their COX-inhibiting mechanism of action [2]. The COX
pathway synthesizes, from arachidonic acids, prostaglandin
D2 and E2, are repressors of inflammatory mediator
release from basophils and mast cells [3]. Therefore,
NSAIDS increases the likelihood of anaphylaxis after
immunotherapy by suppression of prostaglandin D2 and
E2, which would normally inhibit histamine release.
Supporting this mechanism is Marone et al’s study where
higher concentration of NSAIDS and more inhibition of
COX activity correlated with higher release of histamine
[2].
However, in spite of the data about NSAID acting as a
co-factor for anaphylaxis, NSAID avoidance around
immunotherapy cannot be found in practice parameters
from the AAAAI, ACAAI, and CSACI [4,5].
Therefore, as a patient safety precaution, we highly
encourage NSAIDS avoidance to be included for future
immunotherapy practice guidelines. We welcome other
centers to corroborate.
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